GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » EV-to-FCF

CERO (CERo Therapeutics Holdings) EV-to-FCF : -11.74 (As of Dec. 11, 2024)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CERo Therapeutics Holdings's Enterprise Value is $15.48 Mil. CERo Therapeutics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.32 Mil. Therefore, CERo Therapeutics Holdings's EV-to-FCF for today is -11.74.

The historical rank and industry rank for CERo Therapeutics Holdings's EV-to-FCF or its related term are showing as below:

CERO' s EV-to-FCF Range Over the Past 10 Years
Min: -29.9   Med: 0   Max: 0
Current: -11.74

CERO's EV-to-FCF is ranked worse than
100% of 386 companies
in the Biotechnology industry
Industry Median: 8.605 vs CERO: -11.74

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-11), CERo Therapeutics Holdings's stock price is $0.076. CERo Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.240. Therefore, CERo Therapeutics Holdings's PE Ratio (TTM) for today is At Loss.


CERo Therapeutics Holdings EV-to-FCF Historical Data

The historical data trend for CERo Therapeutics Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings EV-to-FCF Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
EV-to-FCF
- -

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only - - -15.50 -11.18 -

Competitive Comparison of CERo Therapeutics Holdings's EV-to-FCF

For the Biotechnology subindustry, CERo Therapeutics Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's EV-to-FCF falls into.



CERo Therapeutics Holdings EV-to-FCF Calculation

CERo Therapeutics Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=15.475/-1.318
=-11.74

CERo Therapeutics Holdings's current Enterprise Value is $15.48 Mil.
CERo Therapeutics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CERo Therapeutics Holdings  (NAS:CERO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CERo Therapeutics Holdings's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.076/-0.240
=At Loss

CERo Therapeutics Holdings's share price for today is $0.076.
CERo Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CERo Therapeutics Holdings EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, South San Francisco, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.